ImmunoBrain Checkpoint (IBC) is a biopharmaceutical company focused on developing a pipeline of novel disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. Our therapies boost the immune system and thereby protect and repair the brain and the central nervous system. IBCs lead program is a proprietary antibody targeting the inhibitory immune checkpoint pathway, PD-1/PD-L1, to treat Alzheimer’s disease. IBC’s novel approach for the treatment of neurodegeneration is based on years of innovative, cutting-edge scientific discoveries made in the lab of Prof. Michal Schwartz at the Weizmann Institute of Science.
July 2016

Register Pro to view more


$25 per month

Sign up to keep browsing

You reached your pageview limit

  • Save profiles to your list
  • Basic search functionality
  • Browse our leading AI database

Select a Table to Export